Mesoblast

Few CMOs equipped to manufacture cell and gene therapies, finds study

11 September 2020 | By Victoria Rees (European Pharmaceutical Review)

A report has said that with only 152 CMOs able to manufacture the 7,000 cell and gene therapies in the pipeline, production bottlenecks may occur.